- Home
- ROIV vs LVS Comparison
ROIV vs LVS Comparison
Compare ROIV & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | LVS |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United Kingdom | United States |
| Employees | 721 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 31.2B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ROIV | LVS |
|---|---|---|
| Price | $38.99 | $40.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $28.94 | ★ $69.21 |
| AVG Volume (30 Days) | ★ 8.5M | 4.9M |
| Earning Date | 05-28-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 19.90 |
| EPS | N/A | ★ 1.38 |
| Revenue | $8,260,000.00 | ★ $13,017,000,000.00 |
| Revenue This Year | N/A | $7.24 |
| Revenue Next Year | $744.61 | $4.49 |
| P/E Ratio | ★ N/A | $28.96 |
| Revenue Growth | N/A | ★ 15.22 |
| 52 Week Low | $14.50 | $39.73 |
| 52 Week High | $42.50 | $70.45 |
Technical Indicators
Market Signals| Indicator | ROIV | LVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 27.35 |
| Support Level | $33.15 | N/A |
| Resistance Level | $42.50 | $55.13 |
| Average True Range (ATR) | 1.45 | 0.98 |
| MACD | 0.05 | -0.34 |
| Stochastic Oscillator | 60.80 | 12.60 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.